These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 37217351)
21. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771 [TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related]
23. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826 [TBL] [Abstract][Full Text] [Related]
24. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases. Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886 [TBL] [Abstract][Full Text] [Related]
25. [The effect of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on peritoneal carcinomatosis from colorectal cancer]. An SL; Zhang K; Ji ZH; Li XB; Yu Y; Zhang YB; Liu G; Li B; Yan GJ; Li Y Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1298-1303. PubMed ID: 34915640 [No Abstract] [Full Text] [Related]
26. The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience. Agalar C; Sokmen S; Arslan C; Altay C; Basara I; Canda AE; Obuz F Tech Coloproctol; 2020 Apr; 24(4):301-308. PubMed ID: 32080800 [TBL] [Abstract][Full Text] [Related]
27. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455 [TBL] [Abstract][Full Text] [Related]
28. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139 [TBL] [Abstract][Full Text] [Related]
29. Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study. Flood MP; Waters PS; Kelly ME; Shields C; Conneely J; Ramsay R; Michael M; Loveday B; Warrier SK; Mulsow J; Heriot AG Surg Oncol; 2021 Jun; 37():101553. PubMed ID: 33839444 [TBL] [Abstract][Full Text] [Related]
30. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
31. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches. Chang SC; Fingerhut A; Chen WT Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126 [TBL] [Abstract][Full Text] [Related]
32. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Cashin PH; Graf W; Nygren P; Mahteme H Ann Surg Oncol; 2013 Dec; 20(13):4183-9. PubMed ID: 23975316 [TBL] [Abstract][Full Text] [Related]
33. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups. Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419 [TBL] [Abstract][Full Text] [Related]
34. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505 [TBL] [Abstract][Full Text] [Related]
35. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O; Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595 [TBL] [Abstract][Full Text] [Related]
36. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis]. Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170 [No Abstract] [Full Text] [Related]
37. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250 [TBL] [Abstract][Full Text] [Related]
38. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis. Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299 [TBL] [Abstract][Full Text] [Related]
39. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer. Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600 [TBL] [Abstract][Full Text] [Related]
40. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP). Cascales-Campos PA; López-López V; Torres-Melero J; Arjona A; Muñoz-Casares FC; Barrios P; Morales R; Pereira F; Bretcha-Boix P; González-Bayón L; González-Moreno S; Gil J Clin Transl Oncol; 2020 Jan; 22(1):130-136. PubMed ID: 31049819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]